[go: up one dir, main page]

EA201890169A1 - Тау-связывающие антитела - Google Patents

Тау-связывающие антитела

Info

Publication number
EA201890169A1
EA201890169A1 EA201890169A EA201890169A EA201890169A1 EA 201890169 A1 EA201890169 A1 EA 201890169A1 EA 201890169 A EA201890169 A EA 201890169A EA 201890169 A EA201890169 A EA 201890169A EA 201890169 A1 EA201890169 A1 EA 201890169A1
Authority
EA
Eurasian Patent Office
Prior art keywords
tau
binding
binding antibodies
binding fragments
taupathy
Prior art date
Application number
EA201890169A
Other languages
English (en)
Other versions
EA036821B1 (ru
Inventor
Керри Луиз Тайсон
Теренс Сьюард Бейкер
Жорж Мере-Коэлло
Партик Дауни
Жан-Филипп Курад
Дэвид Эдвард Ормонд Найт
Original Assignee
Юсб Биофарма Спрл
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Юсб Биофарма Спрл filed Critical Юсб Биофарма Спрл
Publication of EA201890169A1 publication Critical patent/EA201890169A1/ru
Publication of EA036821B1 publication Critical patent/EA036821B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Изобретение относится, в частности, к терапевтическим и диагностическим Тау-связывающим антителам и их связывающим фрагментам, к выделенным молекулам нуклеиновой кислоты, кодирующим легкую и/или тяжелую цепь такого антитела или его связывающего фрагмента, к клонирующему или экспрессирующему вектору, к клетке-хозяину, продуцирующей такое антитело, к применению указанных Тау-связывающих антител или их связывающих фрагментов в качестве терапевтически активного средства, для лечения таупатий, причем таупатии представляют собой болезнь Альцгеймера или прогрессирующий надъядерный паралич. Кроме того, изобретение относится к применению Тау-связывающих антител или их связывающих фрагментов в качестве диагностического средства для диагностирования таупатии.
EA201890169A 2015-07-06 2016-07-05 Тау-связывающие антитела EA036821B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15175519 2015-07-06
PCT/EP2016/065809 WO2017005732A1 (en) 2015-07-06 2016-07-05 Tau-binding antibodies

Publications (2)

Publication Number Publication Date
EA201890169A1 true EA201890169A1 (ru) 2018-10-31
EA036821B1 EA036821B1 (ru) 2020-12-23

Family

ID=53524638

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201890169A EA036821B1 (ru) 2015-07-06 2016-07-05 Тау-связывающие антитела

Country Status (23)

Country Link
US (4) US10344081B2 (ru)
EP (1) EP3319984A1 (ru)
JP (1) JP6937289B2 (ru)
KR (1) KR102742965B1 (ru)
CN (1) CN107849105B (ru)
AR (1) AR105266A1 (ru)
AU (1) AU2016289753C1 (ru)
BR (1) BR112017028101A2 (ru)
CA (1) CA2991264C (ru)
CL (1) CL2018000042A1 (ru)
CO (1) CO2017012974A2 (ru)
EA (1) EA036821B1 (ru)
EC (1) ECSP18000844A (ru)
IL (1) IL256687B (ru)
MA (2) MA41669A1 (ru)
MX (1) MX2017015908A (ru)
PE (1) PE20180499A1 (ru)
PH (1) PH12017502180A1 (ru)
TN (1) TN2017000543A1 (ru)
TW (1) TWI748954B (ru)
UY (1) UY36774A (ru)
WO (1) WO2017005732A1 (ru)
ZA (1) ZA201708128B (ru)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3689904A1 (en) 2013-03-13 2020-08-05 Prothena Biosciences Limited Tau immunotherapy
RU2732122C2 (ru) 2015-06-05 2020-09-11 Дженентек, Инк. Антитела против тау-белка и способы их применения
AU2016289753C1 (en) 2015-07-06 2021-08-05 UCB Biopharma SRL Tau-binding antibodies
AU2016289755C1 (en) 2015-07-06 2021-08-19 UCB Biopharma SRL Tau-binding antibodies
JP7481726B2 (ja) 2016-05-02 2024-05-13 プロセナ バイオサイエンシーズ リミテッド タウ認識抗体
PL3452507T3 (pl) 2016-05-02 2023-01-09 Prothena Biosciences Limited Immunoterapia tau
MX2019006334A (es) 2016-12-07 2019-08-01 Genentech Inc Anticuerpos antitau y métodos de uso.
KR20240035636A (ko) 2016-12-07 2024-03-15 제넨테크, 인크. 항-타우 항체 및 이의 이용 방법
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
WO2018148445A1 (en) 2017-02-08 2018-08-16 Adimab, Llc Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
US20200095327A1 (en) * 2017-02-08 2020-03-26 Dragonfly Therapeutics, Inc. Antibody heavy chain variable domains targeting the nkg2d receptor
MA47499A (fr) 2017-02-17 2019-12-25 Denali Therapeutics Inc Anticorps anti-tau et leurs procédés d'utilisation
KR20240060739A (ko) 2017-02-20 2024-05-08 드래곤플라이 쎄라퓨틱스, 인크. Her2, nkg2d 및 cd16에 결합하는 단백질
JP2018139530A (ja) 2017-02-27 2018-09-13 帝人ファーマ株式会社 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
AU2018263935B2 (en) 2017-05-02 2024-09-26 Prothena Biosciences Limited Antibodies recognizing tau
KR20200058480A (ko) 2017-10-16 2020-05-27 에자이 알앤드디 매니지먼트 가부시키가이샤 항-타우 항체 및 그의 용도
JP2021512630A (ja) 2018-02-08 2021-05-20 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｎｋｇ２ｄ受容体を標的とする抗体可変ドメイン
CA3091424A1 (en) 2018-02-20 2019-08-29 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
EP3894438A1 (en) * 2018-12-13 2021-10-20 INSERM (Institut National de la Santé et de la Recherche Médicale) New anti tau svqivykpv epitope single domain antibody
AU2020231366A1 (en) 2019-03-03 2021-08-12 Prothena Biosciences Limited Antibodies recognizing tau
CR20220505A (es) * 2020-04-08 2023-05-31 Janssen Biotech Inc Anticuerpos anti-phf-tau y usos de estos
JP7512394B2 (ja) 2020-05-06 2024-07-08 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｎｋｇ２ｄ、ｃｄ１６及びｃｌｅｃ１２ａに結合するタンパク質
IL299292A (en) 2020-06-25 2023-02-01 Merck Sharp & Dohme Llc High affinity antibodies targeting tau phosphorylated at serine 413
WO2022144406A1 (en) * 2020-12-29 2022-07-07 Neurimmune Ag Human anti-tau antibodies
US20250034559A1 (en) 2021-11-17 2025-01-30 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
ATE154642T1 (de) 1991-10-25 1997-07-15 Innogenetics Nv Monoklonale antikörper gegen das mikrotubulusassoziierte protein tau.
US7408027B1 (en) 1991-12-06 2008-08-05 Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften Tools for the diagnosis and treatment of Alzheimer's disease
US6010913A (en) 1992-12-14 2000-01-04 N.V. Innogenetics S.A. Isolated human tau peptide
ES2270421T3 (es) 1993-12-21 2007-04-01 Innogenetics N.V. Anticuerpos monoclonales especificos para phf-tau, hibridomas que secretan los mismos, reconocimiento de antigeno por estos anticuerpos y sus aplicaciones.
DE69529906D1 (de) 1994-07-29 2003-04-17 Innogenetics Nv Monoklonale antikörper gegen ein epitop einer gewissen unterklasse oder form von phosphoryliertem tau, hybridome die diese sezernieren,antigenerkennung durch diese antikörper und deren verwendung
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
ES2551439T5 (es) 2003-07-01 2018-11-08 Ucb Biopharma Sprl Fragmentos Fab de anticuerpos modificados
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
CN1721437A (zh) * 2004-07-13 2006-01-18 中南大学 一种与Tau蛋白相关的多肽抗原及抗体
AU2006283532B2 (en) 2005-08-19 2012-04-26 Abbvie Inc. Dual variable domain immunoglobin and uses thereof
WO2007068412A2 (en) 2005-12-12 2007-06-21 Ac Immune Sa A beta 1-42 specific monoclonal antibodies with therapeutic properties
GB0614780D0 (en) 2006-07-25 2006-09-06 Ucb Sa Biological products
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
CA2700714C (en) 2007-09-26 2018-09-11 Ucb Pharma S.A. Dual specificity antibody fusions
US7803371B2 (en) * 2008-03-26 2010-09-28 Epitomics, Inc. Anti-VEGF antibody
CN101307108B (zh) * 2008-06-25 2012-04-04 南京川博生物技术有限公司 抗磷酸化Tau蛋白抗体及其在AD症异常磷酸化Tau蛋白水平测定上的用途
BRPI0918947A2 (pt) 2008-09-26 2015-12-01 Ucb Pharma Sa proteína de fusão de anticorpo
UA107571C2 (xx) 2009-04-03 2015-01-26 Фармацевтична композиція
EP3329932A1 (en) 2009-06-10 2018-06-06 New York University Immunological targeting of pathological tau proteins
US8609097B2 (en) * 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
WO2011013034A1 (en) 2009-07-30 2011-02-03 Pfizer Vaccines Llc Antigenic tau peptides and uses thereof
EP2475682B1 (en) 2009-09-10 2018-01-31 UCB Biopharma SPRL Multivalent antibodies
SG189174A1 (en) 2010-10-11 2013-05-31 Biogen Idec Internat Neuroscience Gmbh Human anti-tau antibodies
US20120244174A1 (en) 2011-01-31 2012-09-27 Intellect Neurosciences Inc. Treatment of tauopathies
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
SMT201800109T1 (it) 2011-09-19 2018-05-02 Axon Neuroscience Se Terapia a base di proteine e diagnosi di una patologia mediata da tau nella malattia di alzheimer
ES2649098T3 (es) 2011-11-11 2018-01-10 Ucb Biopharma Sprl Anticuerpos de unión a albumina y fragmentos de unión de los mismos
SG11201403106SA (en) 2011-12-20 2014-12-30 Janssen Biotech Inc Anti-phf-tau antibodies and their uses
KR102132041B1 (ko) 2012-04-05 2020-07-09 에이씨 이뮨 에스.에이. 인간화된 타우 항체
US9834596B2 (en) 2012-07-03 2017-12-05 Washington University Antibodies to tau
WO2014016737A1 (en) 2012-07-24 2014-01-30 Pfizer Inc. Novel chicken monoclonal antibodies against human phosphorylated tau and uses thereof
GB2507207A (en) 2012-08-16 2014-04-23 Ipierian Inc Treatment of Tauopathies
KR102234324B1 (ko) 2012-12-21 2021-03-31 바이오젠 엠에이 인코포레이티드 인간 항-타우 항체
EP3689904A1 (en) 2013-03-13 2020-08-05 Prothena Biosciences Limited Tau immunotherapy
KR102233349B1 (ko) 2013-03-15 2021-03-31 에이씨 이뮨 에스.에이. 항-타우(tau) 항체 및 사용 방법
LT3083680T (lt) 2013-12-20 2020-04-10 F. Hoffmann-La Roche Ag Humanizuoti anti-tau(ps422) antikūnai ir jų naudojimo būdai
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
JO3576B1 (ar) 2015-02-26 2020-07-05 Lilly Co Eli أجسام مضادة لـ tau واستخداماتها
RU2732122C2 (ru) 2015-06-05 2020-09-11 Дженентек, Инк. Антитела против тау-белка и способы их применения
AU2016289755C1 (en) 2015-07-06 2021-08-19 UCB Biopharma SRL Tau-binding antibodies
AU2016289753C1 (en) 2015-07-06 2021-08-05 UCB Biopharma SRL Tau-binding antibodies
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها

Also Published As

Publication number Publication date
AU2016289753B2 (en) 2020-11-26
AU2016289753A1 (en) 2017-12-14
CL2018000042A1 (es) 2018-06-01
CN107849105B (zh) 2021-09-17
CO2017012974A2 (es) 2018-03-09
KR20180027566A (ko) 2018-03-14
CN107849105A (zh) 2018-03-27
US20230331833A1 (en) 2023-10-19
NZ737843A (en) 2024-05-31
JP2018519833A (ja) 2018-07-26
ZA201708128B (en) 2019-05-29
MA42380A (fr) 2018-05-16
BR112017028101A2 (pt) 2018-09-04
ECSP18000844A (es) 2018-03-31
UY36774A (es) 2017-01-31
KR102742965B1 (ko) 2024-12-13
JP6937289B2 (ja) 2021-09-22
PE20180499A1 (es) 2018-03-09
MX2017015908A (es) 2018-03-15
PH12017502180A1 (en) 2018-05-28
TWI748954B (zh) 2021-12-11
TN2017000543A1 (en) 2019-04-12
CA2991264A1 (en) 2017-01-12
CA2991264C (en) 2023-10-10
AR105266A1 (es) 2017-09-20
WO2017005732A1 (en) 2017-01-12
IL256687A (en) 2018-03-29
TW201713688A (zh) 2017-04-16
US11746145B2 (en) 2023-09-05
US10344081B2 (en) 2019-07-09
US20210139574A1 (en) 2021-05-13
EA036821B1 (ru) 2020-12-23
US20190375829A1 (en) 2019-12-12
MA41669A1 (fr) 2018-05-31
IL256687B (en) 2022-02-01
EP3319984A1 (en) 2018-05-16
AU2016289753C1 (en) 2021-08-05
US20180194832A1 (en) 2018-07-12
US10906966B2 (en) 2021-02-02

Similar Documents

Publication Publication Date Title
EA201890169A1 (ru) Тау-связывающие антитела
EA201890172A1 (ru) Тау-связывающие антитела
EA202091710A1 (ru) Антитела против cd73 и способы их применения
EA201791961A1 (ru) Антитела, специфичные к cd47 и pd-l1
EA201891084A1 (ru) Антитела к il1rap, биспецифические антигенсвязывающие молекулы, которые связываются с il1rap и cd3, и их применение
EA201492101A1 (ru) Антитела против fcrn
EA201492149A1 (ru) St2-антигенсвязывающие белки
EA201690503A1 (ru) Антитела
EA201790530A1 (ru) Агенты, связывающиеся с cd123, и виды их применения
WO2016196975A8 (en) Neutralizing antibodies to hiv-1 env and their use
EA201892774A1 (ru) Антитела
WO2016154003A8 (en) Neutralizing antibodies to gp120 and their use
EA201491494A1 (ru) Нацеливание на гликаны хондроитинсульфаты
PE20180480A1 (es) Anticuerpos de factor xi y metodos de uso
EA201790438A1 (ru) Антигенсвязывающие белки, которые связываются с cxcr5
EA201590138A1 (ru) Оптимизация антител, которые связывают ген активации лимфоцитов 3 (lag-3), и их применение
CL2012002081A1 (es) Anticuerpo humanizado que se une a la cadena alfa del receptor de il-7 humano (cd127); proteina de enlace a antigeno que comprende una o mas regiones determinantes de complementariedad de dicho anticuerpo; molecula de acido nucleico que codifica una anticuerpo o proteina de enalce; vector de expresion, celula huesped recombinante; procedimiento para la produccion de una proteina de enlace a antigeno; procedimiento para tratar enfermedad autoinmune o inflamatoria.
MX2018007630A (es) Anticuerpos contra la metaloproteinasa de matriz 9.
BR112015023797A2 (pt) proteínas de ligação de especificidade dupla dirigidas contra il-1b e/ou il-17
PH12019500571A1 (en) Anti-pd-1 antibodies
EA201591791A1 (ru) Антитела pac1 человека
EA202091315A2 (ru) Антитела человека, связывающиеся с g-белком rsv
EA201690992A1 (ru) Антитела, специфичные к fcrn
MX2014010449A (es) Anticuerpos a metaloproteinasa de matriz 9.
EA201792466A1 (ru) АНТИТЕЛА ПРОТИВ FcRn

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG TJ TM